The ABCs of Alzheimer's prevention are Anthropometric (body fat, visceral fat, lean mass — not BMI), Biomarkers (deep lipid profiling plus inflammation panel), and Cognitive function — a precision-medicine triage framework rather than a one-size-fits-all screen.
2
99.6% of Alzheimer's drugs brought to trial have been abject failures, yet only 0.1 cents of every research dollar goes into prevention versus 99.9 cents into treatment — Richard Isaacson argues even a 90:10 shift would move the needle dramatically.
3
Personalized precision medicine — combining an individual's body composition, lipid subfractions, inflammatory markers, nutritional biomarkers, and genetics — produces better outcomes and creates positive reinforcement that sustains the behavioral changes.
4
20 minutes on the elliptical three times a week will not produce fat loss; high-intensity interval training is the specific recommendation once the anthropometric picture is clear.
WhatAssess body composition via metrics that distinguish metabolically active visceral fat from subcutaneous fat and lean mass: DEXA or equivalent. Determine where fat is stored, not just how much total fat exists. BMI is explicitly excluded as a primary metric.
WhenBaseline assessment for any Alzheimer's prevention workup; reassessed at each follow-up to track change from interventions.
DoseDEXA or visceral fat measurement at baseline; re-measure every 6-12 months or after a significant intervention.
For whomAnyone undergoing Alzheimer's prevention evaluation, particularly those who appear metabolically normal by standard clinical metrics but may have elevated visceral adiposity.
WhyVisceral fat is metabolically active, drives systemic inflammation, and promotes insulin resistance — all downstream drivers of Alzheimer's pathology. BMI misses the most relevant variable. Lean mass tracks metabolic reserve and is independently associated with cognitive resilience.
Attia describes the anthropometric assessment as the result of a deep-dive collaboration with Isaacson. The practical ceiling in most clinics is a DEXA scan, which gives body fat %, lean mass by segment, and estimated visceral fat area. CT-derived visceral fat is more precise but higher radiation and cost. The clinical signal Isaacson is looking for: is this patient insulin-resistant from visceral fat even if their BMI is 24? That answer changes the intervention entirely. A patient with BMI 22 but high visceral fat adiposity gets a very different plan than a patient with BMI 28 who is mostly subcutaneous.
A is anthropometric: we look at body fat, we look at lean mass, we look at is visceral fat — where is the fat. It's not just about weight and BMI — like that's just like the worst.
ABCs Biomarker Panel: deep lipid profiling plus four-category inflammation screen
WhatRun a comprehensive blood panel with four categories: (1) deep lipid: apoB, LDL-P by NMR, particle subtypes; (2) inflammation: hs-CRP (most informative), fibrinogen, myeloperoxidase, LP-PLA2; (3) nutritional biomarkers ideally in RBC not just serum; (4) metabolic markers including insulin and glucose.
WhenBaseline Alzheimer's prevention workup; follow-up timing depends on what is being targeted.
DoseAnnual minimum; more frequent (every 3-6 months) when actively intervening on a specific abnormality.
For whomAnyone over 40 with Alzheimer's risk factors or family history; anyone with cardiovascular risk who has not had advanced lipid testing.
WhyStandard LDL/HDL/triglyceride reporting misses the predictive lipid variables (apoB, particle number, subtypes). hs-CRP is the most actionable inflammation marker in Isaacson's outcomes data. MPO is an emerging vascular cognitive impairment risk factor. LP-PLA2 tracks vascular inflammation specifically.
CaveatsThe clinical response to elevated MPO is not yet standardized. Interleukins (IL-1, IL-6, TNF-alpha) are on Isaacson's wish list but currently excluded from his routine panel due to cost and limited availability.
Isaacson runs deeper lipid profiling than most cardiologists: apoB, LDL particle number, particle subtypes (small dense vs large buoyant LDL). His inflammation panel covers hs-CRP, fibrinogen, MPO, and LP-PLA2. He would add IL-1, IL-6, TNF-alpha, and CD50s if funding allowed. Nutritional biomarkers (omega-3 RBC status, etc.) require a separate lab relationship his practice is working toward. The panel reflects both what is currently actionable and what is emerging — he is explicit that for some markers he is collecting data even before knowing exactly what to do with it.
Mechanism
ApoB counts all atherogenic particles regardless of size; LDL-P measures particle number which drives endothelial penetration; small dense LDL is more atherogenic per particle than large buoyant LDL. hs-CRP reflects systemic inflammation which drives both atherosclerosis and neuroinflammation relevant to Alzheimer's pathology.
The four main categories are cholesterol, but deep dive cholesterol; inflammation — you had apoB, you had LDL-P, you had particles subtype, you really got into it.
Also said
“Now that I see all the results and our outcomes, hs-CRP is probably the most informative. But you know, something like myeloperoxidase is a risk factor for vascular cognitive impairment later — that's a new study.”— Hierarchy of the panel: hs-CRP is the most actionable now; MPO is emerging evidence with growing clinical relevance.
Replace low-intensity elliptical with HIIT when fat loss is the goal
WhatSubstitute high-intensity interval training for chronic low-intensity cardio sessions when the goal is actual fat loss and metabolic improvement. Low-intensity elliptical work (e.g., 20 minutes three times per week) may maintain baseline fitness but does not produce meaningful fat reduction.
WhenWhen anthropometric assessment reveals elevated body fat or visceral fat, and patient's current exercise program is low-intensity steady-state cardio.
DoseSpecifics not provided in this episode; the prescription is to replace or augment current low-intensity sessions with HIIT appropriate to the individual's baseline fitness.
For whomPatients with elevated body fat or visceral fat who have failed to make progress on low-intensity cardio programs.
WhyThe precision-medicine approach requires matching the exercise modality to the metabolic goal. A patient who has been unable to lose weight on 20 minutes of elliptical three times a week is doing the wrong thing for their goal — not working hard enough or not generating the metabolic stimulus required for fat oxidation and body composition change.
Isaacson uses this as the canonical example of why personalized precision medicine outperforms generic advice. The patient says they have never been able to lose weight their whole life. The precision-medicine response is: show them their DEXA, show them their metabolic markers, explain why their current exercise prescription is wrong for their specific picture, and give them the right one. When they redo labs three months later and see the improvement, that positive reinforcement sustains compliance — which is the key behavioral dynamic that generic prescriptions miss.
You were on the elliptical for 20 minutes three times a week. That's not going to get you to lose weight. That may get you to maintain yourself a little bit but not really. You need to do high-intensity interval training, you need to lose body fat.
Personalized precision medicine plan: N-of-1 synthesis of ABCs data
WhatAfter completing the anthropometric and biomarker assessments (and cognitive function component, the C), synthesize findings into a personalized plan that accounts for individual biology, genetics, and specific risk factors — rather than applying a population-level guideline.
WhenAfter baseline ABCs workup is complete; updated as biomarkers are re-measured and interventions are assessed.
DoseOngoing — the plan evolves as biomarker data accumulates and interventions are tested. Isaacson spends approximately one hour per patient reviewing this data.
For whomAnyone motivated to actively reduce Alzheimer's risk, ideally before cognitive symptoms appear; particularly valuable for individuals with family history or known genetic risk (APOE4).
WhyOne-size-fits-all guidelines fail because the metabolic drivers of Alzheimer's vary by individual: one patient's dominant risk factor is visceral fat, another's is dyslipidemia, another's is sleep disruption. Only a personalized approach generates the specific feedback signal needed to sustain behavioral compliance.
CaveatsThis approach requires a physician with sufficient time to interpret complex multi-domain data. Most primary care settings cannot replicate this model; the goal is to develop scalable tools that allow general physicians to apply the framework more efficiently.
Isaacson's clinic has generated 3,000 data points per patient across the ABCs domains. The outcomes data shows that when patients receive the right personalized plan and see their biomarkers improve, they keep doing it. Attia notes that he and Isaacson both benefit from having small practices that allow this depth of engagement — the scaling problem is the central challenge precision medicine faces. Isaacson's free online education platform (two hours of interactive content) is one partial solution for scaling the educational component.
When you do this precision medicine approach — where you look at their cholesterol, inflammation, metabolism, nutrition biomarkers, genetics, and you take all these factors and you look at their body fat and you look at their cognitive function — you can then give them a personalized precision medicine plan.
What's new
Personal practice updates, fresh positions, predictions
5 items
Myeloperoxidase as a novel vascular cognitive impairment risk marker
Isaacson's panel includes myeloperoxidase (MPO) because a new study found it to be a risk factor for vascular cognitive impairment later in life — though he acknowledges the clinical action on an elevated MPO result is still being worked out.
Why this matters: Most clinicians only check hs-CRP and fibrinogen for inflammation; MPO extends the panel into a domain with direct Alzheimer's-relevant vascular pathology and is not standard-of-care anywhere.
Background
Isaacson's inflammation panel already includes hs-CRP and fibrinogen, which he finds most actionable. MPO and LP-PLA2 were added as the evidence base grew, even though the therapeutic response to elevated MPO is not yet established.
The broader inflammation panel Isaacson runs is hs-CRP (most informative in his outcomes data), fibrinogen, myeloperoxidase, and LP-PLA2. He would ideally add IL-1, IL-6, and TNF-alpha but funding constraints have prevented adding interleukins as routine tests. The aspiration is red-blood-cell nutritional biomarkers (more accurate than serum for omega-3 status, for example) but those require a separate lab relationship. This is the practical ceiling in a prevention practice operating at the frontier of what insurance will cover.
You know, something like myeloperoxidase is a risk factor for vascular cognitive impairment later — that's a new study. So I don't exactly know what to do with the inflammatory markers, but we're checking them.
Also said
“Now that I see all the results and our outcomes, hs-CRP is probably the most informative.”— Calibrates the panel: MPO and LP-PLA2 are emerging markers; hs-CRP remains the workhorse with the most actionable signal in Isaacson's own outcomes data.
99.6% Alzheimer's drug failure rate — the case for prevention funding
The success rate of pharmacological trials for Alzheimer's disease is 0.4% — meaning 99.6% of drugs brought to trial have been abject failures. Attia uses this figure to argue that the current 99.9:0.1 treatment-to-prevention funding ratio is indefensible.
Why this matters: Most philanthropic Alzheimer's giving goes to treatment research despite a near-total track record of failure. The statistical argument for redirecting even 10% of that funding to prevention is unusually strong.
Background
Attia has had patients offer $100,000 to Alzheimer's research after losing a family member. His counsel is to give to prevention researchers like Isaacson rather than drug programs, because $100,000 does not buy even five animals in a standard drug study — let alone a funded trial.
The funding argument is structural: prevention trials are squishier because they require behavioral compliance over years, and there is an institutional bias against the idea that you can reliably change how people sleep, meditate, exercise, and eat at population scale. But Attia and Isaacson both argue this is precisely where the highest-leverage opportunity sits. Isaacson's clinic has 3,000 data points per patient and thousands of pages of outcomes data that could produce two papers every few months with two additional full-time hires at $50,000 each — a trivial sum compared to the eight million dollars the clinic has already deployed over five years.
The success rate of pharmacology for Alzheimer's disease is 0.4%. In other words, 99.6% of drugs brought forth to treat Alzheimer's disease are abject failures.
Also said
“$100,000 doesn't buy you five animals to do a study on a drug that has a 99.6% chance of not working.”— Contextualizes the funding argument: the same philanthropic dollar goes enormously further in Isaacson's prevention clinic than in a standard preclinical drug program.
Neurologist running deeper lipid panels than most cardiologists
Attia notes that Richard Isaacson orders more advanced lipid testing — apoB, LDL particle number (LDL-P), and particle subtypes — than most cardiologists, who still report only LDL-C, HDL-C, and triglycerides. The rationale is cardiovascular risk as a direct driver of vascular Alzheimer's pathology.
Why this matters: The standard cardiovascular panel misses the most predictive lipid variables for atherosclerotic risk. A neurologist doing better lipid profiling than most cardiologists is an indictment of standard cardiology practice and a signal for patients to ask for more.
Background
The clinical context is that vascular cognitive impairment — small-vessel disease driven by atherosclerosis and endothelial dysfunction — is a major contributor to Alzheimer's and dementia pathology. Treating lipids aggressively is therefore brain medicine, not just heart medicine.
Isaacson's standard lipid panel includes apolipoprotein B (apoB), LDL particle number by NMR (LDL-P), particle subtypes (small dense LDL versus large buoyant LDL), and likely Lp(a). Attia expresses frustration that cardiologists in his own network are still resistant to these measurements despite robust evidence for their superiority over LDL-C alone. One of his cardiologist patients was initially anti the advanced panel but wants Attia to interpret it — implying even skeptics privately want the data once they see it.
You do more detailed lipid profiling than most cardiologists do. I mean you had apoB, you had LDL-P, you had particles subtype, you really got into it. And I was like why is the neurologist knowing all of this stuff when every cardiologist seems to like still be in the dark ages on this.
Also said
“It drives me crazy. You know we have cardiologists now in the practice and one who was like totally anti — what are you ordering. And he still is anti all that stuff but he really wants to know his numbers and he really wants me to interpret it.”— Even resistant cardiologists privately want advanced lipid data when they become patients themselves — reveals the disconnect between practice and personal belief.
Visceral fat location matters more than total weight or BMI for Alzheimer's risk
Isaacson's anthropometric assessment focuses on body fat percentage, lean mass, and where fat is stored — particularly visceral fat — rather than weight or BMI. Metabolically active visceral fat is the relevant variable for insulin resistance, inflammation, and brain health.
Why this matters: BMI remains the dominant metric in clinical practice despite being a notoriously poor proxy for metabolic health. The A in the ABCs framework explicitly rejects it.
Background
Attia and Isaacson collaborated on a deep dive into body composition that informed the anthropometric component of the framework. The emphasis on visceral fat reflects the well-established link between central adiposity, insulin resistance, and the metabolic drivers of Alzheimer's pathology.
Visceral fat is metabolically active in a way that subcutaneous fat is not — it secretes adipokines, drives systemic inflammation (raising the same IL-6 and CRP that Isaacson monitors in the B biomarkers panel), and promotes insulin resistance which intersects with the glucose metabolism hypothesis of Alzheimer's. The practical implication is that a patient can have a normal BMI with dangerously elevated visceral fat, or an elevated BMI with mostly subcutaneous fat and moderate metabolic risk. A DEXA scan or CT-derived visceral fat measure is required to distinguish them. BMI as the primary screen will miss the most metabolically dangerous patients.
It's not just about weight and BMI — like that's just like the worst. No, it's about body fat, where's the fat, metabolically active.
Precision medicine individualization creates positive reinforcement loop for behavior change
When patients receive a personalized plan based on their own biomarkers, body composition, and genetics — and then see those biomarkers improve — positive reinforcement sustains compliance. Generic advice does not generate the same feedback signal.
Why this matters: Explains mechanistically why lifestyle prescriptions fail at population scale (generic advice) but succeed in precision-medicine clinics (individualized feedback loops). The biomarker data creates the reward circuit.
Isaacson describes seeing three patients in clinic on the same day as the recording, reviewing labs with all three and watching them engage with their own data. The engagement itself is the behavior-change mechanism. Attia connects this to the compliance challenge in prevention research — it is harder to get patients to change sleep, meditation, exercise, and diet than to take a pill, but the upside if you can do those things is much larger. The precision-medicine framework creates the positive feedback loop that generic public-health advice cannot replicate. Isaacson uses this as justification for the time investment: spending an hour with a patient reviewing personalized data produces more durable behavior change than generic prescriptions issued in 15-minute visits.
When you attack it with knowledge about the non-one-size-fits-all approach and the N of one — do everything based on your individual biology and genetics — that's when a person can have the most success. When they have success, it's positive reinforcement.
Recommendations
Products, supplements, and tools mentioned in the episode
An interactive online education platform with two hours of educational content about Alzheimer's prevention, available free of charge. Isaacson built it to scale his prevention education beyond the seven patients per day he can see in clinic.
Isaacson notes that while he is sleeping, over a thousand patients are actively using the tool. He frames it as the only way to impact lives at scale without a larger clinical team. Attia cites it as a model for how precision-medicine-trained physicians can point patients to structured tools even when they lack the time for hour-long individualized visits. The platform covers the ABCs framework in depth: anthropometric assessment, biomarker interpretation, and cognitive function evaluation.
When I'm sleeping, over a thousand patients are on that free education website with two hours of interactive educational content about Alzheimer's prevention. That's how we impact lives.
High-intensity interval training (HIIT) for metabolic fat loss in Alzheimer's prevention
Practice
Isaacson recommends HIIT specifically when the anthropometric assessment shows elevated body fat and the patient's current program is low-intensity steady-state cardio. HIIT generates the metabolic stimulus required for actual fat reduction, not just maintenance.
The HIIT recommendation is the exercise-prescription corollary of the precision-medicine philosophy: match modality to metabolic goal. A patient who says they have never been able to lose weight who is doing 20 minutes on the elliptical three times a week is not failing willpower — they are receiving the wrong prescription for their goal. The personalized plan corrects the mismatch. Fat loss via HIIT connects directly back to the anthropometric A in the ABCs framework — reducing visceral fat removes one of the primary inflammatory and metabolic drivers of Alzheimer's risk.
You were on the elliptical for 20 minutes three times a week. That's not going to get you to lose weight. You need to do high-intensity interval training, you need to lose body fat.
Isaacson believes DHA and EPA are the right omega-3s for Alzheimer's prevention, but acknowledges that without proper RBC biomarkers he does not yet have definitive evidence for the optimal form or dose. The recommendation is tentative pending better biomarker data from his ongoing research.
Isaacson notes that with $75,000 in additional funding he could have run RBC omega-3 biomarkers on his patient cohort and produced definitive evidence about which specific omega-3s to recommend and at what dose. As it stands, he measures omega-3s in serum rather than red blood cells — which is less accurate — limiting the precision of the recommendation. He states he thinks it is DHA and EPA but is explicit that this is not yet fully established by his own data. The aspiration is to run RBC omega-3 indices as standard in the nutritional biomarker component of the ABCs panel.
I think it's DHA and EPA, but I wasn't doing the right biomarkers because I couldn't afford the right tests. Seventy-five thousand dollars extra I could have definitive evidence about which omega-3s to take.
Lines worth pulling out — contrarian, specific, or perfectly phrased
5 items
The success rate of pharmacology for Alzheimer's disease is 0.4%. In other words, 99.6% of drugs brought forth to treat Alzheimer's disease are abject failures.
The single most striking factual claim in the episode — reframes the entire field and makes the statistical case for prevention with one number.
It's not just about weight and BMI — like that's just like the worst. No, it's about body fat, where's the fat, metabolically active.
Clean rejection of BMI as the primary metric for metabolic risk assessment in Alzheimer's prevention — from a neurologist, not an obesity researcher.
Why is the neurologist knowing all of this stuff when every cardiologist seems to like still be in the dark ages on this.
Attia's indictment of standard cardiology practice and a direct prompt for patients to ask for advanced lipid testing from any provider.
It's one thing to get a patient to take their pill; it's quite another thing to get a patient to change the way they sleep, the way they meditate if they do at all, the way they exercise, the way they eat. These things are harder to do. That's the downside. The upside is if you can do those things, I think the evidence is pointing to you can have a much bigger impact.
Honest acknowledgment of why prevention research is institutionally underfunded — and why the payoff is larger than pharmacology when it works.
When you attack it with knowledge about the non-one-size-fits-all approach and the N of one — do everything based on your individual biology and genetics — that's when a person can have the most success. When they have success, it's positive reinforcement.
The core thesis of precision medicine applied to Alzheimer's prevention in one sentence.
Sign in to share feedback
Tell us if this brief hit the mark or missed it — feedback feeds back into the next iteration of the prompt.
Reading is free for everyone. A free account adds the personal layer: save protocols, follow experts, and see how the other experts weigh in on this same topic.
Educational summary of the cited expert source — not medical advice. Open the source recording linked above and consult a qualified physician before acting on any protocol.
